STAAR Surgical Appoints Scott Barnes, MD, as New CMO

October 6, 2017: By Jon Swedien

STAAR Surgical logoSTAAR Surgical has appointed Scott D. Barnes, MD, to be its chief medical officer, a newly created position, the Monrovia, California, company announced Oct. 2.

Barnes will report to Caren Mason, STAAR’s president and CEO.

He will also serve on the executive management team and provide strategic guidance for STAAR’s medical affairs, professional affairs, and product development pathways. As well, Barnes will lead the company’s surgeon training, certification programs, and surgeon working groups, STAAR said.

Since 2012, Barnes has served as chief of ophthalmology services at Womack Army Medical Center in Fort Bragg, North Carolina.

Barnes has personally implanted more than 3,000 implantantable contact lenses in the eyes of soldiers, STAAR said.

He joined Womack in 2004 as chief of ophthalmology and refractive surgery and served as a theater ophthalmology consultant in Iraq and Afghanistan during 2005. In 2006, he returned to Womack as chief of refractive surgery, and, in 2008, he was designated Army Surgeon General A, which is similar to the professor level in a civilian institution.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022